Inspire Medical Systems maintains gross margins above 85% (86.0% in 2026Q3), suggesting its device pricing and cost structure remain resilient even as revenue has slowed to $206.7M in 2026Q3 from a $269.1M peak in 2025Q4.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | $0.14+60.9% vs $0.09 | $207M+1.2% vs $204M |
Q3 2026 Aug 3, 2026 | $0.14+159.3% vs -$0.24 | $201M+3.0% vs $195M |
Q2 2026 May 4, 2026 | $0.10+136.3% vs -$0.28 | $205M+2.3% vs $200M |
Q1 2026 Feb 11, 2026 | $1.65+139.1% vs $0.69 | $269M+1.3% vs $266M |
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
On October 09, 2026, Inspire Medical Systems Inc (INSP) shares rose 3.3% to $68.89, navigating a volatile 52-week range of $38.91 to $147.03. The stock's recent
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRCPR NewswireJOHANNESBURG, Oct. 7, 2026Roche Diagnostics has provided two molecular
MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
Benchmark INSP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Inspire Medical Systems, Inc. (INSP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $63.98 | $1.84B | 18.38 | 13.6% | 11.43% | 12.49% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $90.22 | $2.96B | -77.39 | 26.24% | -4.52% | -22.8% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% |
Inspire Medical Systems, Inc. (INSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Inspire Medical Systems, Inc. (INSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Aug 3, 2026·SEC
Jul 24, 2026·SEC
Get notified when INSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Inspire Medical Systems, Inc. (INSP) stock FAQ — growth, dividends, profitability & financials explained
Inspire Medical Systems, Inc. (INSP) reported $880.9M in revenue over the trailing twelve months. Revenue was $912.0M in fiscal year 2025. That is 5452% more than the $16.4M of fiscal year 2016.
Inspire Medical Systems, Inc. (INSP) revenue fell by 0.2% over the trailing twelve months, compared with the twelve months before.
Yes. Inspire Medical Systems, Inc. (INSP) earned $100.7M in net income over the trailing twelve months (a 11.4% net margin).
Inspire Medical Systems, Inc. (INSP) had a return on equity (ROE) of 12.5% over the trailing twelve months. That is in line with the market's typical 10-15%.
Inspire Medical Systems, Inc. (INSP) generated $97.9M in free cash flow over the trailing twelve months.
